<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947661</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_09_12</org_study_id>
    <nct_id>NCT00947661</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <brief_summary>
    <textblock>
      A single-blind , 12-week, parallel group clinical study is planned to evaluate the efficacy
      and safety of SPARC0912 and Reference0912. SPARC0912 is an experimental drug having similar
      active ingredient but containing a different preservative as that in Reference0912. Patients
      with open angle glaucoma or ocular hypertension will be enrolled and randomly assigned to
      receive either product. One drop will be instilled to the study eye nightly at 8:00 PM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intraocular Pressure From Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>95% CI for the difference between treatment groups in estimated mean change from baseline was computed for each a total of 12 time points (for the reduction in intraocular pressure from baseline to Week 12)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">578</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>SPARC0912</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference0912</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC0912</intervention_name>
    <description>Eye drops, once daily, 12 weeks</description>
    <arm_group_label>SPARC0912</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference0912</intervention_name>
    <description>Eye drops, once daily, 12 weeks</description>
    <arm_group_label>Reference0912</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged ≥ 18 years.

          -  Diagnosis of ocular hypertension (OHT) or primary open angle glaucoma (POAG).

          -  Unmedicated IOP ≥ 22 mmHg in one or both eyes.

          -  Given informed consent.

          -  Women of child bearing potential practicing an acceptable method of birth control with
             a negative urine pregnancy test.

        Exclusion Criteria:

          -  Known lack of ocular hypotensive response to topical ophthalmic, prostaglandin analogs
             (in the opinion of the investigator).

          -  Intraocular conventional surgery or laser surgery within the past six months.

          -  Refractive surgery in study eye (e.g., radial keratotomy, PRK, LASIK, etc.) within the
             past 3 months.

          -  Angle closure glaucoma or a history of acute angle closure treated with a peripheral
             iridotomy.

          -  Ocular trauma within the past 3 months.

          -  Progressive retinal or optic nerve disease apart from glaucoma.

          -  Concurrent infectious/non infectious conjunctivitis, keratitis, or uveitis in either
             eye.

          -  Any abnormality preventing stable applanation tonometry.

          -  Use of contact lens for the duration of the study.

          -  Any opacity or subject uncooperativeness that restricts adequate examination of the
             ocular fundus or anterior chamber.

          -  Clinically significant ocular disease (e.g., corneal edema, uveitis, severe
             keratoconjunctivitis sicca) which might interfere with the study, including
             glaucomatous damage so severe that washout of ocular hypotensive medications is not
             judged safe.

          -  Clinically significant systemic disease which might interfere with the study.

          -  History of non-compliance to medical regimens or unwilling to comply with the study
             protocol.

          -  Participation in another clinical study within the last thirty (30) days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC study site</name>
      <address>
        <city>North Carolina</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <results_first_submitted>December 14, 2015</results_first_submitted>
  <results_first_submitted_qc>April 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2016</results_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma latanoprost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SPARC0912</title>
          <description>SPARC0912 administered once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Reference0912</title>
          <description>Reference0912 administered once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SPARC0912</title>
          <description>SPARC0912 administered once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Reference0912</title>
          <description>Reference0912 administered once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="289"/>
            <count group_id="B2" value="289"/>
            <count group_id="B3" value="578"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="9.59"/>
                    <measurement group_id="B2" value="63.8" spread="11.08"/>
                    <measurement group_id="B3" value="63.4" spread="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intraocular Pressure From Baseline to Week 12</title>
        <description>95% CI for the difference between treatment groups in estimated mean change from baseline was computed for each a total of 12 time points (for the reduction in intraocular pressure from baseline to Week 12)</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent to treat population without LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>SPARC0912</title>
            <description>The change from baseline in intraocular pressure was calculated. A positive change from baseline suggested a reduction from baseline in intraocular pressure. Change from baseline was analyzed using an analysis of covariance methodology, a two-sided 95% CI for the difference between treatment groups in estimated mean change from baseline (i.e., LS means derived from the ANCOVA model) was computed for each time point at each visit (a total of 12 time points at 4 visits i.e. 3 time points at each visit).</description>
          </group>
          <group group_id="O2">
            <title>Reference0912</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure From Baseline to Week 12</title>
          <description>95% CI for the difference between treatment groups in estimated mean change from baseline was computed for each a total of 12 time points (for the reduction in intraocular pressure from baseline to Week 12)</description>
          <population>Intent to treat population without LOCF</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="0.23"/>
                    <measurement group_id="O2" value="6.91" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance included treatment, site, and intraocular pressure group as a covariate. Two-sided 95% confidence interval for the difference between treatment groups in estimated mean change from baseline lease square means was computed for each time point. Non-inferiority of SPARC drug relative to Reference was established if: 95% confidence interval included 0, the upper limit of the 95% CI was &lt;1.5, and upper limit of 95% CI was &lt;1 at most (at least 7 of 12) time point.</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SPARC0912</title>
          <description>SPARC's formulation administered once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Reference0912</title>
          <description>Reference formulation administered once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular edema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain, colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain, Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Shravanti Bhowmik</name_or_title>
      <organization>Sun Pharma Advanced Research Company</organization>
      <email>shravanti.bhowmik@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

